This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following items that are connected to
Hart, Lowell
| Item Type | Name |
|
Concept
|
Receptors, Steroid
|
|
Concept
|
Receptor, erbB-2
|
|
Concept
|
Receptors, Platelet-Derived Growth Factor
|
|
Concept
|
Receptors, Progesterone
|
|
Concept
|
Steroid 17-alpha-Hydroxylase
|
|
Concept
|
Receptor, IGF Type 1
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Receptors, TNF-Related Apoptosis-Inducing Ligand
|
|
Concept
|
Receptors, Estrogen
|
|
Academic Article
|
Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
|
|
Academic Article
|
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
|
|
Academic Article
|
Everolimus plus exemestane as first-line therapy in HR?, HER2? advanced breast cancer in BOLERO-2.
|
|
Academic Article
|
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
|
|
Academic Article
|
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
|
|
Academic Article
|
Phase II study evaluating lapatinib in combination with nab-paclitaxel in HER2-overexpressing metastatic breast cancer patients who have received no more than one prior chemotherapeutic regimen.
|
|
Academic Article
|
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study.
|
|
Academic Article
|
Phase 2, multicenter, open-label study of tigatuzumab (CS-1008), a humanized monoclonal antibody targeting death receptor 5, in combination with gemcitabine in chemotherapy-naive patients with unresectable or metastatic pancreatic cancer.
|
|
Academic Article
|
Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
|
|
Academic Article
|
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial.
|
|
Academic Article
|
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
|
|
Academic Article
|
A phase Ib study of linsitinib (OSI-906), a dual inhibitor of IGF-1R and IR tyrosine kinase, in combination with everolimus as treatment for patients with refractory metastatic colorectal cancer.
|
|
Academic Article
|
Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
|
|
Academic Article
|
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial.
|
|
Academic Article
|
Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial.
|
|
Academic Article
|
Cabazitaxel Plus Lapatinib as Therapy for HER2+ Metastatic Breast Cancer With Intracranial Metastases: Results of a Dose-finding Study.
|
- Receptor
- Platelet Derived Growth Factor
- alpha